A greater percentage of patients in the budesonide group were in clinical remission at week 8 than the placebo group ( intention-to-treat analysis , 80.0 % vs 59.5 % ; P = .072 ; per-protocol analysis , 84.8 % vs 60.6 % ; P = .046 ) .